Description

New data from three randomized clinical trials on the risks and benefits of antithrombotic drugs for patients who have an
indication for such treatment but have had an intracerebral hemorrhage (ICH) have been presented.
The trials were presented at last week's European Stroke Organisation Conference (ESOC) 2021. The investigators did not
reach any definitive conclusions, although the trials show that larger ones are feasible, and these are now being planned.

Period8 Sep 2021

Media contributions

1

Media contributions

  • TitleNew Data on Antithrombotics After ICH: Is There a Net Benefit?
    Media name/outletwww.medscape.com
    Country/TerritoryUnited Kingdom
    Date8/09/21
    DescriptionNew data from three randomized clinical trials on the risks and benefits of antithrombotic drugs for patients who have an indication for such treatment but have had an intracerebral hemorrhage (ICH) have been presented.
    The trials were presented at last week's European Stroke Organisation Conference (ESOC) 2021. The investigators did not reach any definitive conclusions, although the trials show that larger ones are feasible, and these are now being planned.
    "These trials are the first of this kind which are daring to look at antithrombotic drugs in patients with a history of ICH," one of the leading investigators in this field, Rustam Salman, PhD, told Medscape Medical News.
    Producer/AuthorSue Hughes
    PersonsRustam Salman